Shares of Omnicell, Inc. (NASDAQ:OMCL - Get Free Report) gapped down prior to trading on Thursday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $44.38, but opened at $42.07. Omnicell shares last traded at $44.83, with a volume of 50,800 shares changing hands.
The company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%.
Wall Street Analysts Forecast Growth
A number of equities research analysts have commented on OMCL shares. JPMorgan Chase & Co. raised their price objective on Omnicell from $37.00 to $44.00 and gave the stock a "neutral" rating in a research report on Thursday, November 21st. Barclays raised their price target on shares of Omnicell from $39.00 to $58.00 and gave the stock an "equal weight" rating in a report on Thursday, October 31st. StockNews.com lowered shares of Omnicell from a "buy" rating to a "hold" rating in a research note on Tuesday, December 10th. Bank of America decreased their target price on shares of Omnicell from $54.00 to $46.00 and set a "neutral" rating for the company in a research note on Monday, January 6th. Finally, Benchmark restated a "buy" rating and set a $62.00 price target on shares of Omnicell in a report on Tuesday, February 4th. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $52.33.
Read Our Latest Analysis on Omnicell
Insiders Place Their Bets
In other Omnicell news, Director Mark W. Parrish sold 12,000 shares of the business's stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total value of $567,600.00. Following the completion of the sale, the director now owns 58,427 shares of the company's stock, valued at $2,763,597.10. The trade was a 17.04 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 2.64% of the company's stock.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in OMCL. Royce & Associates LP grew its holdings in Omnicell by 4.4% during the fourth quarter. Royce & Associates LP now owns 19,417 shares of the company's stock valued at $864,000 after purchasing an additional 820 shares during the last quarter. Swiss National Bank grew its stake in Omnicell by 0.9% in the 4th quarter. Swiss National Bank now owns 90,500 shares of the company's stock valued at $4,029,000 after buying an additional 800 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its holdings in Omnicell by 46.1% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 429,687 shares of the company's stock worth $19,130,000 after acquiring an additional 135,650 shares during the period. AlphaQuest LLC lifted its position in Omnicell by 307.8% during the 4th quarter. AlphaQuest LLC now owns 3,576 shares of the company's stock worth $159,000 after acquiring an additional 2,699 shares during the last quarter. Finally, Amundi boosted its holdings in Omnicell by 56.0% during the fourth quarter. Amundi now owns 39,309 shares of the company's stock valued at $1,694,000 after acquiring an additional 14,115 shares during the period. 97.70% of the stock is owned by institutional investors.
Omnicell Price Performance
The company has a debt-to-equity ratio of 0.13, a current ratio of 1.37 and a quick ratio of 0.95. The stock's fifty day simple moving average is $44.21 and its 200-day simple moving average is $43.48. The company has a market capitalization of $1.96 billion, a P/E ratio of 157.04, a PEG ratio of 26.98 and a beta of 0.78.
About Omnicell
(
Get Free Report)
Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.
Read More
Before you consider Omnicell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omnicell wasn't on the list.
While Omnicell currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
